Author:

• Lucas Miyake Okumura - Okumura, LM - <lucasokumura@yahoo.com.br>

Co-author(s):

• Mariana Papaléo Rosim - Rosim, MP - <mariana.rosim@mapesolutions.com>
• Bruno Salgado Riveros - Riveros, BS - <bruno.riveros@mapesolutions.com>
• Rosa Camilla Lucchetta - Lucchetta, RC - <rosa.lucchetta@mapesolutions.com>
• Gabriel Ogata Pedro - Pedro, GO - <gabriel.ogata@mapesolutions.com>
• Marcelo Eidi Nita - Nita, ME - <marcelo.nita@mapesolutions.com>

Abstract:

Payment for performance (P4P) is a model of health care professionals and organizations are compensated by achieving predetermined performance measures. In Brazil, P4P has recently come to hepatitis virus C (HCV) treatment, providing the chance for an add-on discussion a previous paper published by Chaves et al., entitled “Public procurement of hepatitis C medicines in Brazil2005 to 2015”. Neither access to HCV nor lower costs preclude better health care. Brazil is on the way of P4P and risk sharing, by promoting HCV prevention, updating HCV guidelines, engaging professionals, industry, health institutions and Real World Data analysts to work towards HCV sustained viral remission. That will be the key to truly improve viral liver diseases-induced morbimortality in Brazil.

Keywords:

hepatitis c virus; payment for performance; direct-acting antivirals; real world data; Brazil.

Content:

Access Issue in Scielo

Other languages: